Skip to main content

ORIGINAL RESEARCH article

Front. Nutr.
Sec. Nutrition and Food Science Technology
Volume 11 - 2024 | doi: 10.3389/fnut.2024.1481203

Dietary Astragalin Confers Protection against Lipopolysaccharide-Induced Intestinal Mucosal Barrier Damage through Mitigating Inflammation and Modulating Intestinal Microbiota

Provisionally accepted
Enhui Tang Enhui Tang Huan Lin Huan Lin Yihao Yang Yihao Yang Jiawen Xu Jiawen Xu Baiwen Lin Baiwen Lin Yang Yang Yang Yang Zijian Huang Zijian Huang Xinlan Wu Xinlan Wu *
  • Guangzhou Medical University, Guangzhou, China

The final, formatted version of the article will be published soon.

    ABSTRACT：The intestinal mucosal barrier (IMB) damage is intricately linked with the onset of numerous intestinal diseases. Astragalin (AS), a flavonoid present in numerous edible plants, exhibits notable antioxidant and anti-inflammatory properties, demonstrating a promising impact on certain intestinal ailments. In this study, our objective was to investigate the protective effects of AS and elucidate the underlying mechanisms by which it mitigates lipopolysaccharide (LPS)-induced damage to the IMB in mice. Throughout the experimental period, the mice were subjected to a 7-day regimen of AS treatment, following which they were administered LPS to induce damage to the IMB. Our results suggested that AS treatment significantly bolstered IMB function. This was evidenced by the enhanced morphology of the small intestine and the elevated expression of tight junction proteins, including ZO-1 and Claudin-1, in addition to increased levels of MUC2 mucin. Moreover, the administration of AS demonstrated a mitigating effect on intestinal inflammation, as indicated by the reduced plasma concentrations of pro-inflammatory cytokines such as IL-6, IL-1β, and TNF-α. Furthermore, AS treatment exerted a positive influence on the composition of the gut microbiota, primarily by augmenting the relative abundance of beneficial bacteria (including Lachnospiracea and Lactobacillus murinus), while simultaneously reducing the prevalence of the harmful bacterium Mucispirillum schaedleri. These results collectively suggest that AS mitigates LPS-induced IMB damage via mitigating inflammation and modulating intestinal microbiota.

    Keywords: Astragalin, intestinal microbiota, intestinal mucosal barrier damage, tight junction, Inflammation

    Received: 15 Aug 2024; Accepted: 19 Sep 2024.

    Copyright: © 2024 Tang, Lin, Yang, Xu, Lin, Yang, Huang and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Xinlan Wu, Guangzhou Medical University, Guangzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.